WOBURN, MA -- Cambria Pharmaceuticals, Inc. announced that it has raised $5.4 million in its first round of venture capital financing.
Cambria is discovering treatments for "serious and progressively disabling neurological disorders." The company uses recently-discovered genetic basis information to engineer new solutions, and intends to focus on ALS (Lou Gehrig's disease" and other serious diseases.
Biogen Idec New Ventures, CommonAngels of Boston and a number of individual investors invested in the round.
The company will use the funding to advance its lead program in ALS through the clinical trial process.
|